<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285983</url>
  </required_header>
  <id_info>
    <org_study_id>Trelagliptin-4004</org_study_id>
    <secondary_id>JapicCTI-205186</secondary_id>
    <nct_id>NCT04285983</nct_id>
  </id_info>
  <brief_title>Specified Drug-Use Survey of Trelagliptin Tablets &quot;Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease&quot;</brief_title>
  <official_title>Specified Drug-Use Survey of Zafatek Tablets &quot;Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in&#xD;
      patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage&#xD;
      renal failure in the routine clinical setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called trelagliptin tablet. This tablet is being&#xD;
      tested to treat people who have type 2 diabetes mellitus complicated by severe renal&#xD;
      impairment or end-stage renal failure.&#xD;
&#xD;
      This study is an observational (non-interventional) study and will look at the long-term&#xD;
      safety of the trelagliptin tablet in the routine clinical setting. The planned number of&#xD;
      observed patients will be approximately 100.&#xD;
&#xD;
      This multi-center observational trial will be conducted in Japan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who had One or More Adverse Reactions</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Adverse reactions are defined as adverse events that are considered as having a causal relationship with pharmaceutical product. Timeframe is defined as a duration from the first dose of trelagliptin up to 12 months (or up to discontinuation of drug administration).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">87</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Trelagliptin 25 mg</arm_group_label>
    <description>Trelagliptin 25 milligrams (mg) tablet, orally, once weekly for up to 12 months. Participants received interventions as part of routine medical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trelagliptin</intervention_name>
    <description>Trelagliptin tablets</description>
    <arm_group_label>Trelagliptin 25 mg</arm_group_label>
    <other_name>Zafatek tablets</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage&#xD;
        renal failure as part of routine medical care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Participants must be type 2 diabetes mellitus patients meeting the following conditions:&#xD;
        Have severe renal impairment or end-stage renal disease, with serum creatinine (mg/dL) or&#xD;
        creatinine clearance (Ccr; mL/min) meeting the following criteria within 3 months before&#xD;
        the start of treatment with this product&#xD;
&#xD;
          -  Serum creatinine (mg/dL)*: male: &gt; 2.4, female: &gt; 2.0&#xD;
&#xD;
          -  Ccr (mL/min): &lt; 30 In patients with end-stage renal disease, this product may be&#xD;
             administered irrespective of the time of hemodialysis.&#xD;
&#xD;
               -  Estimated values corresponding to the Ccr (for persons aged 60 years weighing 65&#xD;
                  kg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Participants with any of the following contraindications for trelagliptin will be&#xD;
        excluded:&#xD;
&#xD;
          1. Patient with severe ketosis, diabetic coma or pre-coma, or type 1 diabetes mellitus&#xD;
&#xD;
          2. Patient with severe infection, perioperative status, or serious trauma&#xD;
&#xD;
          3. Patient with a history of hypersensitivity to any ingredients of trelagliptin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Takeda Selected Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b603c4db2bf003ab4a386</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

